📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
26 announcements match the current filters (relevance ≥ 5).
Innova Captab Q3 FY26 Revenue Jumps 42% YoY to ₹450.3 Cr; PAT Rises 23%
Innova Captab Limited delivered a robust performance in Q3 FY26, with revenue from operations surging 42.3% YoY to ₹450.3 crores. EBITDA followed suit with a 39.6% increase to ₹71.1 crores, although margins contracted slightly by 30 bps to 15.8%. The company reported a 23.2% growth in PAT for the quarter, reaching ₹42.1 crores. Additionally, the receipt of UK-MHRA and PIC/s certifications for its manufacturing units strengthens its international market prospects.
Key Highlights
Q3 FY26 Revenue from operations grew 42.3% YoY to ₹450.3 crores.
EBITDA for the quarter increased 39.6% YoY to ₹71.1 crores with a 15.8% margin.
Profit After Tax (PAT) for Q3 FY26 rose 23.2% YoY to ₹42.1 crores.
Received UK-MHRA GMP certification for Baddi unit and PIC/s compliance for Jammu facility.
9M FY26 Revenue reached ₹1182.2 crores, up 27.3% compared to 9M FY25.
👀 What to Watch
The strong top-line growth and new global regulatory approvals suggest a positive outlook for the CDMO and export business. Investors should maintain a positive stance while monitoring if the company can improve its margins in upcoming quarters.
Innova Captab Q3 Profit Jumps 23% to ₹421.5 Mn; Declares ₹2 Interim Dividend
Innova Captab reported a strong 42.3% YoY increase in consolidated revenue to ₹4,502.93 million for Q3 FY26. Net profit for the quarter rose 23.2% to ₹421.49 million, while basic EPS improved to ₹7.37 from ₹5.97. The company also declared an interim dividend of ₹2 per share (20% of face value) with a record date of January 30, 2026. For the nine-month period ending December 2025, revenue reached ₹11,822.16 million with a total profit of ₹1,028.34 million.
Key Highlights
Consolidated revenue increased by 42.3% YoY to ₹4,502.93 million in Q3 FY26.
Consolidated net profit grew 23.2% YoY to ₹421.49 million for the quarter.
Declared an interim dividend of ₹2 per share (20% of face value) for FY 2025-26.
9M FY26 revenue reached ₹11,822.16 million, up from ₹9,289.35 million in 9M FY25.
Fixed January 30, 2026, as the record date for determining dividend eligibility.
👀 What to Watch
The strong revenue growth and consistent dividend payout reflect positive operational momentum in the pharmaceutical segment. Investors may consider holding or accumulating on dips, given the double-digit profit growth and healthy cash distribution.
Innova Captab Q3 PAT Rises 23% YoY to ₹42.1 Cr; Declares ₹2 Interim Dividend
Innova Captab Limited reported a robust performance for Q3 FY26, with consolidated revenue from operations growing 42.3% YoY to ₹4,502.93 million. Net profit for the quarter increased by 23.2% YoY to ₹421.49 million, showing significant recovery from the previous quarter's ₹296.70 million. The Board has declared an interim dividend of ₹2 per equity share (20% of face value). The record date for the dividend is fixed as January 30, 2026, with the company maintaining a healthy growth trajectory across its pharmaceutical segments.
Key Highlights
Consolidated Revenue from operations increased 42.3% YoY to ₹4,502.93 million.
Net Profit (PAT) grew 23.2% YoY to ₹421.49 million in Q3 FY26.
Interim Dividend of ₹2 per share declared with a Record Date of January 30, 2026.
Quarter-on-Quarter PAT saw a sharp rise of 42.1% from ₹296.70 million in Q2 FY26.
9M FY26 consolidated PAT reached ₹1,028.34 million compared to ₹986.85 million in 9M FY25.
👀 What to Watch
Investors should view the strong sequential and year-on-year growth positively, especially the sharp recovery in margins compared to Q2. The stock remains attractive for those looking for growth in the CDMO and branded generics space, supported by a steady dividend payout.
Innova Captab Declares ₹2 Interim Dividend; Q3 Net Profit Rises 23% YoY to ₹421.5 Million
Innova Captab Limited reported a strong performance for Q3 FY26, with consolidated revenue from operations growing 42.3% YoY to ₹4,502.93 million. Net profit for the quarter increased by 23.2% YoY to ₹421.49 million, while EPS rose to ₹7.37 from ₹5.97 in the previous year's corresponding quarter. The Board has declared an interim dividend of ₹2 per equity share (20% of face value) with a record date of January 30, 2026. For the nine-month period ended December 2025, the company achieved a total income of ₹11,880.72 million.
Key Highlights
Consolidated Revenue from operations surged 42.3% YoY to ₹4,502.93 million in Q3 FY26.
Net Profit for the quarter stood at ₹421.49 million, up from ₹342.04 million in Q3 FY25.
Declared an interim dividend of ₹2 per equity share (20% of face value ₹10) for FY 2025-26.
Nine-month consolidated net profit reached ₹1,028.34 million compared to ₹986.85 million YoY.
Record date for the interim dividend is fixed as Friday, January 30, 2026.
👀 What to Watch
Investors may view the strong revenue growth and dividend declaration as a sign of healthy cash flows and operational scaling. The stock remains a key watch in the pharmaceutical CDMO space given its consistent earnings growth.
Innova Captab Q3 FY26 Revenue Jumps 42% YoY to ₹4,503 Mn; Declares ₹2 Interim Dividend
Innova Captab Limited reported a robust performance for the quarter ended December 31, 2025, with consolidated revenue from operations rising 42.3% YoY to ₹4,502.93 million. Net profit for the quarter grew 23.2% YoY to ₹421.49 million, showing a strong recovery from the previous quarter's ₹296.70 million. The Board also declared an interim dividend of ₹2 per share (20% of face value) with a record date of January 30, 2026. This growth is supported by the consolidation of subsidiaries including Sharon Bio-Medicine and Univentis Medicare.
Key Highlights
Consolidated Revenue from Operations increased 42.3% YoY to ₹4,502.93 million.
Net Profit (PAT) grew 23.2% YoY to ₹421.49 million from ₹342.04 million in the previous year.
Declared an interim dividend of ₹2 per equity share with a record date of January 30, 2026.
Quarter-on-quarter (QoQ) profit showed a significant jump of 42% from ₹296.70 million in Q2 FY26.
Finance costs increased to ₹39.50 million in Q3 FY26 compared to just ₹1.66 million in Q3 FY25.
👀 What to Watch
Investors should take note of the strong top-line growth and the company's ability to maintain dividend payouts. The significant QoQ recovery in margins is a positive sign, though rising finance costs warrant continued monitoring.
Innova Captab Board to Meet Jan 23 for Q3 Results and Interim Dividend Consideration
Innova Captab Limited has scheduled a board meeting on January 23, 2026, to approve the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The board will also consider a proposal for declaring an interim dividend for the financial year 2025-26. If approved, the company has already fixed January 30, 2026, as the record date to determine shareholder eligibility for the payout. This dual announcement indicates potential cash returns to shareholders alongside the quarterly performance update.
Key Highlights
Board meeting scheduled for January 23, 2026, to review Q3 and 9M FY26 financial performance.
Proposal for an interim dividend for FY 2025-26 to be considered during the meeting.
Record date for the potential interim dividend is fixed as January 30, 2026.
Trading window for insiders remains closed from January 1, 2026, until 48 hours after the results are declared.
👀 What to Watch
Investors should monitor the January 23 announcement for the dividend amount and earnings growth to assess the company's yield and operational health.
